Patents Assigned to Baker Norton Pharmaceuticals, Inc.
-
Patent number: 7056898Abstract: Provided are compounds and compositions thereof that are useful for treating inflammation, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such compounds and compositions of the invention to treat patients suffering from, or predisposed to develop inflammation.Type: GrantFiled: April 16, 2002Date of Patent: June 6, 2006Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Tahir Ahmed, Gregory Smith
-
Patent number: 7041640Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: March 15, 2004Date of Patent: May 9, 2006Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20050267201Abstract: Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.Type: ApplicationFiled: June 24, 2005Publication date: December 1, 2005Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Jose Gutierrez-Rocca, Janice Cacace, Sami Selim, Robert Testman, J. Rutledge
-
Patent number: 6964946Abstract: Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0–70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.Type: GrantFiled: April 6, 1998Date of Patent: November 15, 2005Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Jose C. Gutierrez-Rocca, Janice L. Cacace, Sami Selim, Robert Testman, J. Michael Rutledge
-
Publication number: 20050238634Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: April 13, 2005Publication date: October 27, 2005Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth Duchin, Sami Selim
-
Patent number: 6936583Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: GrantFiled: March 5, 2004Date of Patent: August 30, 2005Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6818615Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: September 12, 2002Date of Patent: November 16, 2004Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20040176439Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: March 15, 2004Publication date: September 9, 2004Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Salim
-
Publication number: 20040171532Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: ApplicationFiled: March 5, 2004Publication date: September 2, 2004Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6730698Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: GrantFiled: February 6, 2002Date of Patent: May 4, 2004Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6610735Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: April 10, 2001Date of Patent: August 26, 2003Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20030069301Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: September 12, 2002Publication date: April 10, 2003Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6451285Abstract: Provided are pressurized metered dose inhalers containing stable formulations of a &bgr;-agonist drug in suspension or solution. Also provided are aerosol formulations suitable for inhalation therapy containing a &bgr;-agonist drug in suspension or solution.Type: GrantFiled: June 19, 1998Date of Patent: September 17, 2002Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Frank E. Blondino, Michael Brucato, Maria W. Buenafe
-
Patent number: 6395770Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxaneresponsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: GrantFiled: August 28, 1999Date of Patent: May 28, 2002Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6334445Abstract: Compositions and methods are provided which are effective in treating ovarian cancer. These compositions are easily administered by long term infusion schedules of at least 72 hours, and can be given in dosages that are safe and provide for manageable side effects. These methods and compositions for treating ovarian cancer in patients whose tumors progressed or failed to respond during prior taxane treatment of shorter duration. Surprisingly, it has been shown that longer infusion periods, such as 96 hours, give substantially lower neuropathy and certain other side effects than shorter term infusions.Type: GrantFiled: March 27, 1998Date of Patent: January 1, 2002Assignee: Baker Norton Pharmaceuticals, Inc.Inventor: Karl Mettinger
-
Patent number: 6290930Abstract: Provided is a solution aerosol formulation adapted for use in a pressurized aerosol container. The aerosol formulation is formulated from a composition containing Budesonide, at least one fluoroalkane propellant, and a cosolvent present in an amount that dissolves or solubilizes the Budesonide in the mixture of cosolvent and propellant.Type: GrantFiled: December 18, 1998Date of Patent: September 18, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Frank E. Blondino, Michael Brucato, Maria Buenafe, Kelly A. Cavanaugh, Raul A. Medina
-
Patent number: 6284800Abstract: The present invention comprises methods and compositions for the treatment of bronchorestrictive disorders, including asthma, in humans or animals. The methods and compositions are effective in treatment of inflammatory responses, such as those found in asthma and other related pathologies.Type: GrantFiled: March 13, 1998Date of Patent: September 4, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Tahir Ahmed
-
Patent number: 6245805Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: October 16, 1996Date of Patent: June 12, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6235725Abstract: The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the identification of compositions and methods which are capable of preventing tolerance to &bgr;2-adrenergic agonists. The methods and compositions according to the invention are also useful as analytical tools for functional studies and as combination therapeutic tools.Type: GrantFiled: July 28, 1999Date of Patent: May 22, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventor: Tahir Ahmed
-
Patent number: D439325Type: GrantFiled: February 8, 2000Date of Patent: March 20, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventor: Phillip Frost